ReShape Lifesciences, Inc. (RSLS): יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

ReShape Lifesciences (RSLS) aims to expand B2B distribution of Lap-Band systems, yet liquidity shortages and asset restructuring following the merger with a biopharma entity create risks for operational stability. This price chart reflects the EV/EBITDA dynamics, which currently stands at . While the business relies on minimally invasive weight loss methods, it faces significant pressure due to the popularity of modern injectable drugs.

The EV/EBITDA multiple determines the business value inclusive of net debt relative to operating profit, allowing for an assessment of the asset's real value without the influence of the tax regime. For ReShape Lifesciences (RSLS), which is restructuring its surgical segment under pressure from GLP-1 drugs, the company's EV/EBITDA valuation trend serves as an indicator of debt sustainability. Analyzing this chart helps determine whether the capital is overvalued amid a shifting market paradigm.